Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Lindeman

Showing results (281-290 of 292) with videos related to

Pageof 30
Sort By:
Cancer Discovery|December 7, 2018
A Phase Ib Dose-Escalation and Expansion Study of the BCL2 Inhibitor Venetoclax Combined with Tamoxifen in ER and BCL2-Positive Metastatic Breast CancerSheau W Lok, James R Whittle, François Vaillant, et al.
Cell Death & Disease|March 13, 2021
Preclinical small molecule WEHI-7326 overcomes drug resistance and elicits response in patient-derived xenograft models of human treatment-refractory tumorsChristoph Grohmann, Francesca Walker, Mark Devlin, et al.
The New England Journal of Medicine|August 8, 2014
Breast-cancer risk in families with mutations in PALB2Antonis C Antoniou, Silvia Casadei, Tuomas Heikkinen, et al.
BJU International|September 16, 2010
Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: preliminary analysis of the results of the IMPACT studyAnita V Mitra, Elizabeth K Bancroft, Yolanda Barbachano, et al.
NPJ Breast Cancer|May 12, 2023
PREDICT validity for prognosis of breast cancer patients with pathogenic BRCA1/2 variantsTaru A Muranen, Anna Morra, Sofia Khan, et al.
Cell Chemical Biology|August 9, 2023
Discovery of a highly potent, selective, orally bioavailable inhibitor of KAT6A/B histone acetyltransferases with efficacy against KAT6A-high ER+ breast cancerShikhar Sharma, Chi-Yeh Chung, Sean Uryu, et al.
The Lancet. Oncology|October 22, 2021
A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective studyElizabeth K Bancroft, Elizabeth C Page, Mark N Brook, et al.
British Journal of Cancer|January 5, 2018
Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predispositionChristos Mikropoulos, Christina G Hutten Selkirk, Sibel Saya, et al.
European Urology|February 4, 2014
Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT studyElizabeth K Bancroft, Elizabeth C Page, Elena Castro, et al.
European Urology|February 19, 2026
Targeted Prostate Cancer Screening in Carriers of BRCA1 or BRCA2 Pathogenic Germline Variants Detects Clinically Relevant Disease: 5-year Results from the IMPACT StudyElizabeth K Bancroft, Elizabeth C Page, Jana McHugh, et al.
Pageof 30

Showing results (281-290 of 292) with videos related to

Sort By:
Pageof 30
Cancer Discovery|December 7, 2018
A Phase Ib Dose-Escalation and Expansion Study of the BCL2 Inhibitor Venetoclax Combined with Tamoxifen in ER and BCL2-Positive Metastatic Breast CancerSheau W Lok, James R Whittle, François Vaillant, et al.
Cell Death & Disease|March 13, 2021
Preclinical small molecule WEHI-7326 overcomes drug resistance and elicits response in patient-derived xenograft models of human treatment-refractory tumorsChristoph Grohmann, Francesca Walker, Mark Devlin, et al.
The New England Journal of Medicine|August 8, 2014
Breast-cancer risk in families with mutations in PALB2Antonis C Antoniou, Silvia Casadei, Tuomas Heikkinen, et al.
BJU International|September 16, 2010
Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: preliminary analysis of the results of the IMPACT studyAnita V Mitra, Elizabeth K Bancroft, Yolanda Barbachano, et al.
NPJ Breast Cancer|May 12, 2023
PREDICT validity for prognosis of breast cancer patients with pathogenic BRCA1/2 variantsTaru A Muranen, Anna Morra, Sofia Khan, et al.
Cell Chemical Biology|August 9, 2023
Discovery of a highly potent, selective, orally bioavailable inhibitor of KAT6A/B histone acetyltransferases with efficacy against KAT6A-high ER+ breast cancerShikhar Sharma, Chi-Yeh Chung, Sean Uryu, et al.
The Lancet. Oncology|October 22, 2021
A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective studyElizabeth K Bancroft, Elizabeth C Page, Mark N Brook, et al.
British Journal of Cancer|January 5, 2018
Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predispositionChristos Mikropoulos, Christina G Hutten Selkirk, Sibel Saya, et al.
European Urology|February 4, 2014
Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT studyElizabeth K Bancroft, Elizabeth C Page, Elena Castro, et al.
European Urology|February 19, 2026
Targeted Prostate Cancer Screening in Carriers of BRCA1 or BRCA2 Pathogenic Germline Variants Detects Clinically Relevant Disease: 5-year Results from the IMPACT StudyElizabeth K Bancroft, Elizabeth C Page, Jana McHugh, et al.
Pageof 30